02/24/21 7:00 AMNasdaq : CERE, CEREWCerevel Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, March 24, 2021Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter and full year 2020 financial results on Wednesday, March 24, 2021,RHEA-AIneutral
02/23/21 7:00 AMNasdaq : CERE, CEREWCerevel Therapeutics to Present at the Cowen 41st Annual Health Care ConferenceCerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that the company will participate in the upcoming Cowen 41st Annual Health Care Conference. Date :RHEA-AIneutral
01/28/21 7:00 AMNasdaq : CERE, CEREWCerevel Therapeutics Hosts Inaugural Virtual R&D Event to Review Darigabat (CVL-865) and Provide Overview of Key Preclinical ProgramsDarigabat now the international nonproprietary name (INN) for CVL-865, a Phase 2 GABA Positive Allosteric Modulator Company Expects to File U.S. IND Applications in 2021 for PDE4B and Kappa Opioid Receptor Agonist Preclinical Programs Live webcast today from 9:00 to 11:00 a.m. EST CAMBRIDGE, Mass.,RHEA-AIneutral
01/21/21 7:00 AMNasdaq : CERE, CEREWCerevel Therapeutics Announces the Appointments of Deval Patrick and Deborah Baron to its Board of DirectorsCerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has appointed the Honorable Deval Patrick and Deborah Baron to serve as independent members of its BoardRHEA-AIvery positive
12/14/20 7:00 AMNasdaq : CERE, CEREWCerevel Therapeutics to Host Inaugural Virtual R&D Event Cerevel Therapeutics (Nasdaq: CERE), aRHEA-AIneutral
12/08/20 7:00 AMNasdaq : CERE, CEREWCerevel Therapeutics Announces the Appointment of Dr. Ruth McKernan to its Board of DirectorsCerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has added Ruth McKernan, Ph.D., CBE, FMedSci, to serve as an independent member of itsRHEA-AIneutral
12/04/20 7:00 AMNasdaq : CERE, CEREWCerevel Therapeutics to Host Investor Webcast Moderated by StifelCerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host a live webcast providing a current corporate overview, followed by a moderated question andRHEA-AIneutral
11/23/20 7:00 AMNasdaq : CERE, CEREWCerevel Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual ConferenceCerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced Chairperson and Chief Executive Officer Tony Coles, M.D., will participate in a fireside chat at the Evercore ISIRHEA-AIneutral
11/16/20 6:30 AMNasdaq : CERE, CEREWCerevel Therapeutics Announces Third Quarter 2020 Financial Results and Key Business HighlightsParticipants dosed in clinical trials for lead programs in schizophrenia, epilepsy, anxiety and Parkinson's disease Debuted as publicly traded entity under symbol CERE Net proceeds of approximately $440 million raised from completed business combination transaction with ARYA Sciences AcquisitionRHEA-AIneutral
11/04/20 7:00 AMNasdaq : CERE, CEREWCerevel Therapeutics to Present at Upcoming Virtual Investor ConferencesCerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in three upcoming virtual investor conferences during the monthRHEA-AIneutral
